CMS Efforts On Value-Based Payments Should Focus On Removing Barriers, PhRMA Says
Executive Summary
The Pharmaceutical Research and Manufacturers of America says the US Centers for Medicare and Medicaid Services should not itself initiate experiments with value-based payment approaches. Any demonstrations led by agency's CMMI should focus on "holistic" approaches to health costs.
You may also be interested in...
HHS Secretary Alex Azar Talks Rebate Changes, But Not Eliminating Discounts Altogether
Details on anticipated changes to rebate practices are in demand. HHS Secretary Azar talked about changes that would still allow negotiated discounts at the point of sale during a presentation at the FT Pharma Pricing and Value Summit.
HHS Secretary Alex Azar Talks Rebate Changes, But Not Eliminating Discounts Altogether
Details on anticipated changes to rebate practices are in demand. HHS Secretary Azar talked about changes that would still allow negotiated discounts at the point of sale during a presentation at the FT Pharma Pricing and Value Summit.
Value-Based Payment Experiments For Drugs To Be Key Focus For CMMI, Director Says
Recently-installed Center for Medicare and Medicaid Innovation Chief Adam Boehler says payment lab will play a role in the Administration’s overall approach to lowering prescription drug costs.